The status of Nrf2 is a key determinant of the effect of System Xc−GSH/GPX4 axis-targeted therapy in HCC, and therefore it is necessary to improve efficacy by inhibiting Nrf2 expression. This evidence concerns the gene GPX4 and hepatocellular carcinoma.